278. Huge lymphatic malformation with cervicofacial lesion
19 clinical trials,   23 drugs   (DrugBank: 7 drugs),   5 drug target genes,   62 drug target pathways

Searched query = "Huge lymphatic malformation with cervicofacial lesion", "Huge lymphatic malformation", "Lymphatic malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs031180265
10/08/201613/03/2019Study of bleomycin and OK-432 combined scletotherapy for LMsClinical study of bleomycin and OK-432 combined local injection sclerotherapy for intractable lymphatic malformations Lymphangioma (lymphatic malformation, common or cystic lymphatic malformation), and other lymphatic
lymphangioma, lymphatic malformation,;D18.1
OK-432 and bleomycin slolution (0.05 kE / mL and 0.5 mg / mL, respectively) will be injected into the lesion with water-soluble contrast agent Maximum dose of bleomycin is 10 mg /dose and 5 mg/kgBW.Cumulative maximum dose in repeated treatment is 10 mg/kgBWFujino AkihiroNULLNot RecruitingNot applicableNot applicableBoth21N/AJapan